Education
About Us
Working with TipRanks
Follow Us
Stayble Therapeutics AB (DE:4K4)
FRANKFURT:4K4
Total Valuation
Stayble Therapeutics AB has a market cap or net worth of €1.47M. The enterprise value is €14.42M.
Market Cap€1.47M
Enterprise Value€14.42M
Share Statistics
Stayble Therapeutics AB has 64,359,795 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64,359,795
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Stayble Therapeutics AB’s return on equity (ROE) is -1.81 and return on invested capital (ROIC) is -165.68%.
Return on Equity (ROE)-1.81
Return on Assets (ROA)-1.34
Return on Invested Capital (ROIC)-165.68%
Return on Capital Employed (ROCE)-1.66
Revenue Per Employee0.00
Profits Per Employee-6.21M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Stayble Therapeutics AB is ―. Stayble Therapeutics AB’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.81
Price to Fair Value2.81
Price to FCF-1.32
Price to Operating Cash Flow-1.14
PEG Ratio0.02
Income Statement
In the last 12 months, Stayble Therapeutics AB had revenue of 0.00 and earned -12.42M in profits. Earnings per share was -0.33.
Revenue0.00
Gross Profit-148.21K
Operating Income-12.79M
Pretax Income-12.42M
Net Income-12.42M
EBITDA-12.22M
Earnings Per Share (EPS)-0.33
Cash Flow
In the last 12 months, operating cash flow was -6.78M and capital expenditures 0.00, giving a free cash flow of -6.78M billion.
Operating Cash Flow-6.78M
Free Cash Flow-6.78M
Free Cash Flow per Share-0.11
Dividends & Yields
Stayble Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.16
52-Week Price Change-33.33%
50-Day Moving Average0.02
200-Day Moving Average0.03
Relative Strength Index (RSI)54.90
Average Volume (3m)0.00
Important Dates
Stayble Therapeutics AB upcoming earnings date is Feb 25, 2026, TBA (Confirmed).
Last Earnings DateNov 19, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
Stayble Therapeutics AB as a current ratio of 2.35, with Debt / Equity ratio of 8.55%
Current Ratio2.35
Quick Ratio2.35
Debt to Market Cap0.04
Net Debt to EBITDA0.11
Interest Coverage Ratio-246.04
Taxes
In the past 12 months, Stayble Therapeutics AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Stayble Therapeutics AB EV to EBITDA ratio is -1.47, with an EV/FCF ratio of -1.23.
EV to Sales0.00
EV to EBITDA-1.47
EV to Free Cash Flow-1.23
EV to Operating Cash Flow-1.23
Balance Sheet
Stayble Therapeutics AB has €3.80M in cash and marketable securities with €850.00K in debt, giving a net cash position of €2.95M billion.
Cash & Marketable Securities€3.80M
Total Debt€850.00K
Net Cash€2.95M
Net Cash Per Share€0.05
Tangible Book Value Per Share€0.03
Margins
Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Stayble Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―